Patents-Review.com
ClassID:

110416 ⎘

C12N2740/16171 - CPC Classification

Classification description:

Reverse transcribing RNA viruses; Details; Retroviridae; Human Immunodeficiency Virus, HIV concerning HIV env Demonstrated effect

Recent Application in this class:
#1
20260151474
2026-06-04

CH505 ENVELOPES TO ENGAGE AND MATURE CD4 BINDING SITE NEUTRALIZING ANTIBODIES

 #2
20260144860
2026-05-28

HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE

 #3
20250073328
2025-03-06

COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HIV INFECTION

 #4
20240424082
2024-12-26

GLYCAN-MASKED ENGINEERED OUTER DOMAINS OF HIV-1 GP120 AND THEIR USE

 #5
20240277829
2024-08-22

HIV-1 VACCINATION AND SAMT-247 MICROBICIDE TO PREVENT HIV-1 INFECTION

 #6
20240261388
2024-08-08

Extreme Polyvalency Induces Potent Cross-Clade Cellular and Humoral Responses in Rabbits and Non-human Primates

 #7
20240000919
2024-01-04

MODIFIED ENVELOPE PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS AND USE THEREOF

 #8
20230338507
2023-10-26

HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE

 #9
20230075330
2023-03-09

CHIMERIC HIV VIRUS-LIKE PARTICLES

 #10
20220152194
2022-05-19

Glycan-masked engineered outer domains of HIV-1 gp120 and their use

 #11
20210220468
2021-07-22

Immunodeficiency virus type 1 (HIV-1) mutant envelope proteins

 #12
20210138061
2021-05-13

Extreme polyvalency induces potent cross-clade cellular and humoral responses in rabbits and non-human primates

 #13
20200397890
2020-12-24

Antiviral vaccines with improved cellular immunogenicity

 #14
20200323976
2020-10-15

Biochemically stabilized HIV-1 Env trimer vaccine

 #15
20200316191
2020-10-08

Methods and compositions for treating and preventing HIV

 #16
20200230229
2020-07-23

HIV-1 Env fusion peptide immunogens and their use

 #17
20200121783
2020-04-23

Glycan-masked engineered outer domains of HIV-1 gp120 and their use

 #18
20200113997
2020-04-16

Compositions and methods for inducing HIV-1 antibodies

 #19
20200101152
2020-04-02

Methods and compositions for treating and preventing HIV

 #20
20200087382
2020-03-19

Polyclonal antibodies produced using HIV-1 trimeric envelope glycoprotein subunits

 #21
20200023056
2020-01-23

Biochemically stabilized HIV-1 Env trimer vaccine

 #22
20190321462
2019-10-24

Recombinant adenoviruses encoding mosaic human immunodeficiency virus (HIV) Env, Gag, and Pol antigens

 #23
20190314492
2019-10-17

Antiviral vaccines with improved cellular immunogenicity

 #24
20190298820
2019-10-03

Recombinant HIV epitopes and uses thereof

 #25
20190247491
2019-08-15

Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment

 #26
20190240319
2019-08-08

Biochemically stabilized HIV-1 env trimer vaccine

 #27
20190216915
2019-07-18

Transgenic VERO-CD4/CCR5 cell line

 #28
20190184008
2019-06-20

Methods and compositions for treating and preventing HIV

 #29
20190142937
2019-05-16

Vaccines with biomolecular adjuvants

 #30
20180369366
2018-12-27

Methods and compositions related to accelerated humoral affinity

 #31
20180333481
2018-11-22

Cross-reactive T-cell epitopes of HIV, SIV, and FIV for vaccines in humans and cats

 #32
20180207259
2018-07-26

Biochemically stabilized HIV-1 Env trimer vaccine

 #33
20180194809
2018-07-12

Engineered outer domain (eOD) of HIV GP120, mutants and use thereof

 #34
20180064803
2018-03-08

Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment

 #35
20170360920
2017-12-21

METHOD AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF A HIV INFECTION

 #36
20170290907
2017-10-12

Biochemically stabilized HIV-1 Env trimer vaccine

 #37
20170266272
2017-09-21

Transgenic Vero-CD4/CCR5 cell line

 #38
20170239344
2017-08-24

Antiviral vaccines with improved cellular immunogenicity

 #39
20170182152
2017-06-29

Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin

 #40
20170165355
2017-06-15

Synthetic human immunodeficiency virus (HIV) envelope antigen, vectors, and compositions thereof

 #41
20170112922
2017-04-27

Attenuated recombinant vesicular stomatitis virus vaccine vectors comprising modified matrix proteins

 #42
20170095551
2017-04-06

Replication-competent VSV-HIV Env vaccines

 #43
20160375129
2016-12-29

Dimeric scaffold peptides comprising HIV-1 GP120 and GP41 epitopes

 #44
20160354462
2016-12-08

Vaccine and therapeutic delivery system

 #45
20160333055
2016-11-17

HIV-1 V3 mimotopes capable of inducing cross-clade neutralizing antibodies

 #46
20160279230
2016-09-29

Soluble HIV-1 envelope glycoprotein trimers

 #47
20160243215
2016-08-25

Stabilized human immunodeficiency virus (HIV) clade C envelope (Env) trimer vaccines and methods of using same

 #48
20160243169
2016-08-25

DUAL VECTOR FOR INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS

 #49
20160237123
2016-08-18

Compositions and methods comprising hydrocarbon-stapled polypeptides

 #50
20160235836
2016-08-18

Mosaic HIV envelope immunogenic polypeptides

 #51
20160152667
2016-06-02

COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS

 #52
20160144019
2016-05-26

Stabilized HIV-1 peptide constructs comprising the gp120 C5 domain and gp41 hydrophilic domain

 #53
20160067334
2016-03-10

Vaccines with biomolecular adjuvants

 #54
20160045591
2016-02-18

Vaccine and therapeutic delivery system

 #55
20160024156
2016-01-28

Antiviral vaccines with improved cellular immunogenicity

 #56
20160002319
2016-01-07

HIV Antigens and Antibodies

 #57
20150313990
2015-11-05

HIV therapeutics and methods of making and using same

 #58
20150246112
2015-09-03

Replicating recombinant adenovirus vectors, compositions, and methods of use thereof

 #59
20150183835
2015-07-02

STABILIZED GP120

 #60
20120263720
2012-10-18

Peptide constructs derived from the GP120 C5 domain and GP41 transmembrane domain

 #61
20120201794
2012-08-09

DUAL VECTOR FOR INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS

 #62
20120183533
2012-07-19

MIMOTOPES OF HIV ENV

 #63
20120087946
2012-04-12

Recombinant bacterium and methods of antigen and nucleic acid delivery

 #64
20120076812
2012-03-29

Antiviral vaccines with improved cellular immunogenicity

 #65
20120046221
2012-02-23

Albumin fusion proteins

 #66
20120045472
2012-02-23

Biochemically stabilized HIV-1 ENV trimer vaccine

 #67
20110318352
2011-12-29

Compositions and methods for the treatment of viral infections

 #68
20110200636
2011-08-18

Method for inducing a multiclade immune response against HIV utilizing a multigene and multiclade immunogen

 #69
20110009312
2011-01-13

Albumin fusion proteins

 #70
20090232830
2009-09-17

Modified HIV-1 envelope proteins

 #71
20090214588
2009-08-27

Vaccines against aids comprising cmv/r-nucleic acid constructs

 #72
20090099073
2009-04-16

Albumin Fusion Proteins

 #73
20090093402
2009-04-09

Albumin Fusion Proteins

 #74
20080213886
2008-09-04

Albumin fusion proteins

 #75
20080167240
2008-07-10

Albumin Fusion Proteins

 #76
20080167239
2008-07-10

Albumin fusion proteins comprising insulin polypeptides

 #77
20080161243
2008-07-03

Albumin Fusion Proteins

 #78
20080153751
2008-06-26

G-CSF-albumin fusion proteins

 #79
20080146503
2008-06-19

Albumin fusion proteins

 #80
20070259815
2007-11-08

Albumin fusion proteins

 #81
20070244047
2007-10-18

Albumin fusion proteins

 #82
20060276396
2006-12-07

Albumin fusion proteins

 #83
20060194735
2006-08-31

Albumin fusion proteins

 #84
20050186664
2005-08-25

Albumin fusion proteins comprising GLP-1 polypeptides

 #85
15705549
2020-11-10

Extreme polyvalency induces potent cross-clade cellular and humoral responses in rabbits and non-human primates